A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.

被引：0
|
作者：
Shapiro, Geoffrey
Supko, Jeffrey G.
Cho, Daniel C.
Hilton, John Frederick
Hadfield, Matthew
Pruitt-Thompson, Salida
Bordoli-Trachsela, Eveline
Zvereva, Nela
Wolanski, Andrew
Sato-DiLorenzo, Aya
Gotthardt, Susan
Fox, Edward A.
Verselis, Sigitas Jonas
Kumar, Ashok
Holden, Sylvia A.
Ram, Siya
Chafai-Fadela, Karima
Harding, Kimberly
Menon, Krishna E.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] KARD Sci, Beverly, MA USA
[5] Cellceutix, Beverly, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2627
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
    Infante, Jeffrey R.
    Cohen, Roger B.
    Kim, Kevin B.
    Burris, Howard A., III
    Curt, Gregory
    Emeribe, Ugochi
    Clemett, Delyth
    Tomkinson, Helen K.
    LoRusso, Patricia M.
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (05) : 576 - 588
  • [42] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
    LoRusso, Patricia M.
    Infante, Jeffrey R.
    Kim, Kevin B.
    Burris, Howard A., III
    Curt, Gregory
    Emeribe, Ugochi
    Clemett, Delyth
    Tomkinson, Helen K.
    Cohen, Roger B.
    BMC CANCER, 2017, 17
  • [43] A phase I dose-escalation and immune biomarker study of intravenous FF-10832, liposomal gemcitabine, in patients with advanced solid tumors.
    Borazanci, Erkut Hasan
    Falchook, Gerald Steven
    Abbas, Atif
    Wheeler, Catherine A.
    Maier, Gary
    Johansen, Mary
    Sedivy, Paula
    Subach, Ruth Ann
    Sen, Shiraj
    Jones, Suzanne Fields
    Ioroi, Tadaaki
    Matsumoto, Takeshi
    Suzuki, Takeaki
    Madden, Timothy
    Hamilton, Erika Paige
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] A phase I dose-escalation and pk study of continuous oral rucaparib in patients with advanced solid tumors
    Flynn, M.
    Shapiro, G.
    LoRusso, P.
    Kristeleit, R.
    Patel, M.
    Infante, J.
    Giordano, H.
    Borrow, J.
    Jaw-Tsai, S.
    Burris, H., III
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S185 - S185
  • [45] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
    Patricia M. LoRusso
    Jeffrey R. Infante
    Kevin B. Kim
    Howard A. Burris
    Gregory Curt
    Ugochi Emeribe
    Delyth Clemett
    Helen K. Tomkinson
    Roger B. Cohen
    BMC Cancer, 17
  • [46] A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.
    Im, Seock-Ah
    Lee, SeungHwan
    Lee, Keun Wook
    Lee, Youngjoo
    Sohn, Joohyuk
    Kim, Jee Hyun
    Im, Young-Hyuck
    Park, Kyong Hwa
    Oh, Do-Youn
    Kim, Min Hwan
    Park, Yeon Hee
    Kim, Tae Min
    Choi, Yoon Ji
    Lee, Chang-Seok
    Park, Jiseon
    Baek, Nam Seok
    Choi, MiKyung
    Kim, John
    Yu, Eunyoung
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors: a phase I dose-escalation and pharmacokinetic (PK) study
    Traynor, A.
    Sandler, A.
    Schiller, J. H.
    Ilagan, J.
    Harper, K.
    VerMeulen, W.
    Liu, G.
    Tye, L.
    Chao, R.
    Robert, F.
    EJC SUPPLEMENTS, 2007, 5 (04): : 110 - 110
  • [48] Phase 1, first-in-human, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654, a PIM kinase inhibitor, in patients with advanced solid tumors
    Garrido-Laguna, Ignacio
    Dillon, Patrick M.
    Kabir, Sujan
    Mei, Jian
    Wade, Mark L.
    Yang, Huyuan
    Stapinski, Carl
    Foulks, Jason M.
    Warner, Steven L.
    Whatcott, Clifford
    Lebedinsky, Claudia
    Fu, Siqing
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [49] Phase 1 dose-escalation study of ACT001 in patients with recurrent glioblastoma and other advanced solid tumors.
    Lickliter, Jason D.
    Jennens, Ross
    Lemech, Charlotte Rose
    Kichenadasse, Ganessan
    Cai, Dongpo
    Su, Steven Yung-Chang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors
    Sun, Yongkun
    Yang, Lin
    Hao, Xuezhi
    Liu, Yutao
    Zhang, Jinwen
    Ning, Zhiqiang
    Shi, Yuankai
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
12345